BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18958631)

  • 1. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO
    Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B; Kılıç N; Şimşek E; Dallar Y
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
    Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
    Koldas M; Gummus M; Seker M; Seval H; Hulya K; Dane F; Kural A; Gumus A; Salepci T; Turhal NS
    Clin Lung Cancer; 2008 Mar; 9(2):112-5. PubMed ID: 18501098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.
    Erem C; Kocak M; Hacihasanoglu A; Yilmaz M
    J Endocrinol Invest; 2008 Jun; 31(6):537-41. PubMed ID: 18591887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B; Comlekci A; Ali Ozcan M; Demir T; Yener S; Demirkan F; Yuksel F; Yesil S
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
    Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy.
    Yango J; Alexopoulou O; Eeckhoudt S; Hermans C; Daumerie C
    Eur J Endocrinol; 2011 Apr; 164(4):599-603. PubMed ID: 21257724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J; Tymcio J
    Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
    Verkleij CJ; Stuijver DJ; van Zaane B; Squizzato A; Brandjes DP; Büller HR; Meijers JC; Gerdes VE
    Thromb Haemost; 2013 Feb; 109(2):214-20. PubMed ID: 23197299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
    Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood coagulation and fibrinolytic activity in hypothyroidism.
    Erem C; Kavgaci H; Ersöz HO; Hacihasanoglu A; Ukinç K; Karti SS; Deger O; Telatari M
    Int J Clin Pract; 2003 Mar; 57(2):78-81. PubMed ID: 12661786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
    Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
    Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
    Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.